Zymeworks Inc. Common Shares (ZYME) Social Stream



Zymeworks Inc. Common Shares (ZYME): $12.02

0.31 (+2.65%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

B

Add ZYME to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#39 of 356

in industry

ZYMEWORKS INC (ZYME) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering ZYME.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-04 8 $74 $28 $48.875 $10.56 362.83%
2021-11-10 8 $74 $27 $48.75 $10.56 361.65%
2021-11-17 9 $74 $27 $47.875 $10.56 353.36%
2021-12-10 9 $74 $27 $47.875 $10.56 353.36%
2021-12-14 9 $74 $27 $45.375 $10.56 329.69%
2022-01-24 8 $51 $27 $40.857 $10.56 286.9%
2022-02-01 8 $51 $27 $37.571 $10.56 255.79%
2022-02-24 8 $51 $18 $34.714 $10.56 228.73%
2022-03-15 9 $44 $15 $28.875 $10.56 173.44%
2022-04-13 9 $44 $15 $27.125 $10.56 156.87%
2022-05-02 8 $44 $15 $27.142 $10.56 157.03%
2022-05-05 8 $44 $14 $25.5 $10.56 141.48%
2022-05-23 8 $40 $14 $24.625 $10.56 133.19%
2022-05-27 8 $40 $14 $22.875 $10.56 116.62%
2022-08-04 8 $40 $14 $22.375 $10.56 111.88%
2022-08-09 8 $40 $7.7 $20.1 $10.56 90.34%
2022-08-10 8 $40 $7.7 $19.337 $10.56 83.12%
2022-09-05 9 $40 $7.7 $20.189 $10.56 91.18%
2022-09-14 9 $40 $7.7 $19.522 $10.56 84.87%
2022-10-04 9 $40 $7.7 $18.47 $10.56 74.91%
2022-10-24 10 $40 $7.7 $17.62 $10.56 66.86%
2022-10-26 10 $40 $7.7 $16.52 $10.56 56.44%
2022-10-28 10 $40 $7 $15.82 $10.56 49.81%
2022-11-09 10 $21 $7 $12.62 $10.56 19.51%
2022-11-21 10 $21 $7 $12.82 $10.56 21.4%
2022-12-20 10 $21 $7 $13.15 $10.56 24.53%
2022-12-22 11 $21 $8 $12.863 $10.56 21.81%
2023-01-17 11 $21 $8 $12.681 $10.56 20.09%
2023-03-07 11 $21 $8 $13.045 $10.56 23.53%
2023-03-08 11 $21 $8 $13.136 $10.56 24.39%
2023-03-10 11 $18.5 $8 $12.55 $10.56 18.84%
2023-03-21 10 $18.5 $8 $12.85 $10.56 21.69%
2023-04-25 10 $18.5 $8 $12.95 $10.56 22.63%
2023-05-08 9 $18.5 $8 $12.95 $10.56 22.63%
2023-05-09 9 $19 $8 $13.05 $10.56 23.58%
2023-08-15 9 $19 $8 $13.15 $10.56 24.53%
2023-11-13 8 $19 $8 $12.666 $10.56 19.94%
2023-12-01 10 $19 $8 $12.555 $10.56 18.89%

The Trend in the Analyst Price Target


ZYME's average price target has moved down $40.74 over the prior 43 months.

Over the past 45 weeks, ZYME's average upside potential has been 53.87%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-03-10 10 18.5 8 12.772 7.93 61.06%
2023-03-10 11 18.5 8 12.772 7.93 61.06%
2023-08-15 9 19.0 8 12.555 7.42 69.2%
2023-12-01 10 19.0 8 13.000 9.15 42.08%
2023-12-01 9 19.0 8 13.000 9.15 42.08%

ZYME Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.89 5 0 4 0 0 9

The Trend in the Broker Recommendations


Over the past 17 months, ZYME's average broker recommendation rating worsened by 0.3.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • In terms of how ZYMEWORKS INC fares relative to all US stocks, note that its variance in analysts' estimates is lower than -4115.25% of that group.
  • In terms of how ZYMEWORKS INC fares relative to all US stocks, note that its average analyst price target is greater than 1238.77% of that group.
  • To contextualize these metrics, consider that out of stocks in the mid market cap category, ZYMEWORKS INC's upside potential (average analyst target price relative to current price) is greater than 3225.94% of them.
  • ZYME has a greater number of analysts covering the stock than 3045.3% of stocks in the mid market cap category.

In the Pharmaceutical Products industry, HCM, ORGO, and BPMC are the three stocks most similar to ZYMEWORKS INC regarding the price target and analyst recommendation information presented here.

What is the outlook for ZYME? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!